These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 6144615)

  • 61. Dysphagia in movement disorders.
    Logemann JA
    Adv Neurol; 1988; 49():307-16. PubMed ID: 2964174
    [No Abstract]   [Full Text] [Related]  

  • 62. Pathophysiology of pediatric movement disorders.
    Sanger TD
    J Child Neurol; 2003 Sep; 18 Suppl 1():S9-24. PubMed ID: 13677568
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Symptomatology of movement disorders in children].
    Czochanska J
    Med Wieku Rozwoj; 2001; 5(2):173-8. PubMed ID: 11679682
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The extrapyramidal system: a review of function.
    Klawans HL; Barr A
    Clin Neuropharmacol; 1983; 6 Suppl 1():S3-8. PubMed ID: 6357434
    [No Abstract]   [Full Text] [Related]  

  • 65. Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
    Wray SR; Melville GN; Grell GA; Edge PC
    West Indian Med J; 1981 Sep; 30(3):107-18. PubMed ID: 6117153
    [No Abstract]   [Full Text] [Related]  

  • 66. Movement disorder emergencies in childhood.
    Kirkham FJ; Haywood P; Kashyape P; Borbone J; Lording A; Pryde K; Cox M; Keslake J; Smith M; Cuthbertson L; Murugan V; Mackie S; Thomas NH; Whitney A; Forrest KM; Parker A; Forsyth R; Kipps CM
    Eur J Paediatr Neurol; 2011 Sep; 15(5):390-404. PubMed ID: 21835657
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Movement disorders and Creutzfeldt-Jakob disease: a review.
    Maltête D; Guyant-Maréchal L; Mihout B; Hannequin D
    Parkinsonism Relat Disord; 2006 Mar; 12(2):65-71. PubMed ID: 16364674
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A polygraphic test for the diagnosis of amyotrophic choreo-acanthocytosis.
    Bramanti P; Ricci RM; Candela L; Serra S; Di Perri R
    Acta Neurol (Napoli); 1987 Apr; 9(2):134-8. PubMed ID: 3508349
    [No Abstract]   [Full Text] [Related]  

  • 69. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
    De Reuck J; De Weweire M; Van Maele G; Santens P
    J Neurol Sci; 2005 Apr; 231(1-2):35-9. PubMed ID: 15792818
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Movement disorders ii: chorea, dystonia, myoclonus, and tremor.
    Mink JW; Zinner SH
    Pediatr Rev; 2010 Jul; 31(7):287-94; quiz 295. PubMed ID: 20595442
    [No Abstract]   [Full Text] [Related]  

  • 71. Pediatric movement disorders.
    Saunders-Pullman R; Braun I; Bressman S
    Child Adolesc Psychiatr Clin N Am; 1999 Oct; 8(4):747-65, viii. PubMed ID: 10553201
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Movement disorder emergencies.
    Frucht SJ
    Curr Neurol Neurosci Rep; 2005 Jul; 5(4):284-93. PubMed ID: 15987612
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pearls: hyperkinetic movement disorders.
    Reich SG
    Semin Neurol; 2010 Feb; 30(1):15-22. PubMed ID: 20127576
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Studies of a decussate inhibiting reflex in the region of the quadriceps femoris muscle in man].
    Klepel H; Rabending G
    Psychiatr Neurol Med Psychol (Leipz); 1970 Feb; 22(2):54-8. PubMed ID: 4251547
    [No Abstract]   [Full Text] [Related]  

  • 75. How to assess motor impairment in writer's cramp.
    Zeuner KE; Peller M; Knutzen A; Holler I; Münchau A; Hallett M; Deuschl G; Siebner HR
    Mov Disord; 2007 Jun; 22(8):1102-9. PubMed ID: 17230462
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Hunter C; Jankovic J
    Mov Disord; 2007 Jan; 22(2):193-7. PubMed ID: 17133512
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Movement disorder emergencies.
    Poston KL; Frucht SJ
    J Neurol; 2008 Aug; 255 Suppl 4():2-13. PubMed ID: 18821080
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
    Furukawa Y; Filiano JJ; Kish SJ
    Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rating scale for psychogenic movement disorders: scale development and clinimetric testing.
    Hinson VK; Cubo E; Comella CL; Goetz CG; Leurgans S
    Mov Disord; 2005 Dec; 20(12):1592-7. PubMed ID: 16108025
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Movement disorders in miscellaneous disorders--inherited metabolic diseases].
    Mizuguchi M; Kamoshita S
    Nihon Rinsho; 1993 Nov; 51(11):2919-23. PubMed ID: 8277572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.